NCT04327011 2020-03-30A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511Tocagen Inc.Phase 1 Terminated65 enrolled
NCT04105374 2020-03-24Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed GlioblastomaNRG OncologyPhase 2/3 Withdrawn
NCT02576665 2020-02-07A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)Tocagen Inc.Phase 1 Terminated21 enrolled
NCT01470794 2018-05-21Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain TumorTocagen Inc.Phase 1 Completed58 enrolled
NCT01985256 2018-05-21Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain TumorTocagen Inc.Phase 1 Completed17 enrolled